Abstract
Introduction/BackgroundIn the phase 3 RUBY trial (NCT03981796) dostarlimab + carboplatin-paclitaxel (CP) significantly improved progression-free survival (PFS) vs CP alone in the mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H; hazard ratio [HR], 0.28)...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
